Research Nester published a report titled Dextromethorphan Market: Global Demand Analysis & Opportunity Outlook 2031which delivers detailed overview of the global dextromethorphan market in terms of market segmentation by product type, application, end-user, and by region.

Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.

The global dextromethorphan market is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2022 – 2031. The market is segmented on the basis of application into cold, acute and chronic bronchitis, bronchial asthma, sore throat, tuberculosis, and others. Out of these, the acute and chronic bronchitis segment is anticipated to hold a substantial share over the forecast period owing to the increasing prevalence of bronchitis especially amongst the population living low- and middle-income countries.

Request Report Sample@

The global dextromethorphan market is estimated to witness growth owing to the increasing prevalence of diseases, such as, asthma, bronchitis, and tuberculosis, along with the increasing global geriatric population. According to the data by the World Health Organization (WHO), chronic bronchitis caused 3.23 million deaths, and asthma caused 461,000 deaths in 2019 globally. With the rise in incidences of such diseases, the health awareness amongst the public is also rising, which is further projected to boost the market growth.

On the basis of geographical analysis, the global dextromethorphan market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in the North America region is anticipated to gain the largest market share throughout the forecast period, on account of the increasing cases of bronchitis and bronchial asthma, along with availability of advanced medications and healthcare facilities in the region. According to the data by Center for Disease Control and Prevention (CDC), 46.3 individuals out of every 100,000 population die due to chronic lower respiratory diseases in the U.S.  

The research is global in nature and covers detailed analysis on the market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). In addition, analysis comprising market size, Y-O-Y growth & opportunity analysis, market players’ competitive study, investment opportunities, demand for future outlook etc. has also been covered and displayed in the research report.

High Prevalence of Asthma and Other Respiratory Diseases to Propel the Market Growth

According to the data by the WHO, 262 million people were diagnosed with asthma in 2019.

Asthma is one of the most common respiratory diseases, which is prevalent amongst the geriatric and pediatric population globally. The growing prevalence of asthma is anticipated to boost the demand for dextromethorphan, as it is used to suppress extreme cough. Dextromethorphan is very effective in reducing and controlling the cough during an asthma attack, which is estimated to fuel the market growth.

However, increasing circulation of generic drugs is expected to operate as key restraint to the growth of global dextromethorphan market over the forecast period.

This report also provides the existing competitive scenario of some of the key players of the global dextromethorphan market which includes company profiling of AstraZeneca PLC, FibroGen, Inc., Novartis AG, Abbott Laboratories, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Sunovion Pharmaceuticals Inc., Aurobindo Pharma Limited, and Zydus Pharmaceuticals Inc. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global dextromethorphan market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.     

Request Report Sample@

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.

Contact for more Info:

AJ Daniel


U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919